Prostaglandin metabolite induces inhibition of TRPA1 and channel-dependent nociception
Molecular Pain volume 8, Article number: 75 (2012)
The Transient Receptor Potential (TRP) ion channel TRPA1 is a key player in pain pathways. Irritant chemicals activate ion channel TRPA1 via covalent modification of N-terminal cysteines. We and others have shown that 15-Deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2) similarly activates TRPA1 and causes channel-dependent nociception. Paradoxically, 15d-PGJ2 can also be anti-nociceptive in several pain models. Here we hypothesized that activation and subsequent desensitization of TRPA1 in dorsal root ganglion (DRG) neurons underlies the anti-nociceptive property of 15d-PGJ2. To investigate this, we utilized a battery of behavioral assays and intracellular Ca2+ imaging in DRG neurons to test if pre-treatment with 15d-PGJ2 inhibited TRPA1 to subsequent stimulation.
Intraplantar pre-injection of 15d-PGJ2, in contrast to mustard oil (AITC), attenuated acute nocifensive responses to subsequent injections of 15d-PGJ2 and AITC, but not capsaicin (CAP). Intraplantar 15d-PGJ2—administered after the induction of inflammation—reduced mechanical hypersensitivity in the Complete Freund’s Adjuvant (CFA) model for up to 2 h post-injection. The 15d-PGJ2-mediated reduction in mechanical hypersensitivity is dependent on TRPA1, as this effect was absent in TRPA1 knockout mice. Ca2+ imaging studies of DRG neurons demonstrated that 15d-PGJ2 pre-exposure reduced the magnitude and number of neuronal responses to AITC, but not CAP. AITC responses were not reduced when neurons were pre-exposed to 15d-PGJ2 combined with HC-030031 (TRPA1 antagonist), demonstrating that inhibitory effects of 15d-PGJ2 depend on TRPA1 activation. Single daily doses of 15d-PGJ2, administered during the course of 4 days in the CFA model, effectively reversed mechanical hypersensitivity without apparent tolerance or toxicity.
Taken together, our data support the hypothesis that 15d-PGJ2 induces activation followed by persistent inhibition of TRPA1 channels in DRG sensory neurons in vitro and in vivo. Moreover, we demonstrate novel evidence that 15d-PGJ2 is analgesic in mouse models of pain via a TRPA1-dependent mechanism. Collectively, our studies support that TRPA1 agonists may be useful as pain therapeutics.
Transient receptor potential cation channel subfamily A member 1 (TRPA1) was first identified as a channel activated by noxious cold (~10-17°C) and was thus included in the temperature-gated subfamily termed “thermoTRPs” [1, 2]. Whether TRPA1 is directly activated by cold and if it plays a role in thermosensation in vivo remain equivocal and debated issues in the somatosensory field [3–5]. However, its activation by a variety of noxious chemicals is widely accepted. The catalogue of TRPA1 chemical agonists is burgeoning and includes a variety of exogenous, as well as endogenous, compounds. We and others identified 15d-PGJ2, a multi-functional prostaglandin molecule, as an endogenous TRPA1 activator. Similar to other TRPA1 agonists, intraplantar (ipl.) administration of high concentrations (relative to physiological levels) of 15d-PGJ2 causes TRPA1-dependent nocifensive behavior [6–9].
15d-PGJ2, one of three J-series prostaglandin D2 metabolites, is the most recently discovered prostaglandin with a proposed role as an endogenous anti-inflammatory agent . 15d-PGJ2 activates molecules in anti-inflammatory pathways through covalent modification of cysteine residues. This occurs because of its reactive cyclopentenone ring, which readily reacts with nucleophilic cysteine groups through the Michael addition reaction . This has been shown using non-reactive analogues of 15d-PGJ2 and by mutagenizing cysteine residues of target proteins such as IkappaB kinase and PPARγ [12–16]. Similarly, cysteine residues of TRPA1 can be modified by certain electrophilic agonists, which leads to activation of the channel by chemicals of this class [11, 17, 18].
Recent findings support that 15d-PGJ2 also exhibits anti-nociceptive properties [9, 19, 20]. Here we demonstrate a novel TRPA1-dependent anti-nociceptive modality of 15d-PGJ2 in acute nociception and mechanical hypersensitivity. Although the pro- and anti-nociceptive effects of 15d-PGJ2 may seem mutually exclusive, we propose a mechanism based on our data that reconciles these seemingly opposing effects. We hypothesize that 15d-PGJ2 is anti-nociceptive owing in part to its ability to activate and desensitize TRPA1 in peripheral nociceptive fibers.
Our findings support this hypothesis. Peripheral injection of a pro-nociceptive and behaviorally desensitizing dose of 15d-PGJ2 produces an attenuation of acute nocifensive behavior induced by AITC, whereas AITC itself does not produce such effects. Correspondingly, we find that 15d-PGJ2 produces a marked inhibition of subsequent responses to AITC in DRG neurons. When administered after the induction of inflammation, 15d-PGJ2 reduces mechanical hypersensitivity in WT but not TRPA1 knockout (TRPA1−/−) mice, arguing that these analgesic effects are mediated via the channel. Taken together our data suggest that 15d-PGJ2 induces a reduction of chemical and mechanical nociception via initial activation and subsequent inhibition of TRPA1. Results also indicate that this property may be unique to 15d-PGJ2 as an endogenous TRPA1 activator, as AITC did not have the same effects in behavioral assays or in DRG neurons.
Effects of 15d-PGJ2 on mechanosensitivity
We hypothesized that 15d-PGJ2 is anti-nociceptive owing in part to its ability to activate, and subsequently desensitize, TRPA1. We set out to test whether 15d-PGJ2 is anti-nociceptive in pain models in which a role of TRPA1 is implicated. After the induction of mechanical hypersensitivity by CFA, TRPA1-selective antagonists AP-18 and HC-030031 ameliorate post-CFA mechanical thresholds in WT but not TRPA1−/− mice [21–23]. Therefore, we utilized the CFA model to investigate whether 15d-PGJ2 could reverse inflammatory mechanical hypersensitivity.
In separate groups of mice, we measured mechanical thresholds using the up and down method at baseline and 24 h post-CFA injection (day 1, Figure 1A). One day after CFA injection, we injected 1.5 or 15 mM 15d-PGJ2 (10 μL) into the plantar hindpaw 1 h prior to von Frey measurements. As shown in Figure 1A, 15 mM 15d-PGJ2 induced a marked reversal of mechanical hypersensitivity relative to vehicle (and 1.5 mM 15d-PGJ2). The effect was maximal at 2 h post injection. In contrast, 15d-PGJ2 had no effect on heat hypersensitivity as measured with the Hargreaves assay, suggesting that the effect of 15d-PGJ2 is modality specific (Figure 1B). Administering 15d-PGJ2 prior to the induction of inflammation by CFA had no effect on mechanical thresholds in CFA- or vehicle-injected mice (data not shown, see also below).
Previous studies characterizing the analgesic effects of 15d-PGJ2 do not report whether the compound alters baseline mechanical sensitivities in naïve/un-injured rodents [9, 19, 20]. Therefore, we also investigated whether ipl. injection of 15 mM 15d-PGJ2, administered 1 h prior to von Frey testing, caused any change in mechanical thresholds relative to vehicle-injected controls. As shown in Figure 1C, mechanical sensitivities of 15d-PGJ2 and vehicle-injected mice did not significantly differ. This indicates that 15d-PGJ2 does not generate mechanical hypo- or hypersensitivity. In contrast, pre-injection of an equivalent concentration of AITC (15 mM) caused a significant reduction in paw withdrawal threshold, indicative of hyperalgesia (Figure 1C). These results are similar to studies showing that AITC and cinnamaldehyde induce significant mechanical hyperalgesia in rats [24, 25]. Furthermore, our data also suggest disparate in vivo effects of the two TRPA1 agonists 15d-PGJ2 and AITC.
15d-PGJ2 and AITC evoke equivalent nocifensive behavior
We reasoned that the different pharmacological effects of 15d-PGJ2 and AITC could be due to their relative potencies in vivo. Though the two TRPA1-specific compounds have similar in vitro EC50 values, in vivo potencies have not been directly compared . Therefore, we performed dose–response analysis using two concentrations of 1.5 and 15 mM 15d-PGJ2 or AITC (10 μL, ipl.). To determine both the magnitude and duration of nocifensive behaviors at each dose of the two compounds, we recorded at 10-min intervals for 1 h. Figure 2 illustrates the total nocifensive response at 10-min increments (A-B) and the total duration (C) of nocifensive responses during the course of 40 min at each concentration of 15d-PGJ2 and AITC. 15d-PGJ2- and AITC-induced nocifensive behaviors consisted of licking, deliberate lifting and shaking of the injected hindpaw. Nocifensive behaviors subsided approximately 40 min after injection of 15 mM or 1.5 mM of 15d-PGJ2 or AITC (Figure 2 A-B, data not shown). The efficacy of 15 and 1.5 mM 15d-PGJ2 and AITC in producing total nocifensive responses were equivalent (Figure 1C). For both 15d-PGJ2 and AITC, 0.15 mM doses did not induce significant nocifensive behaviors compared to vehicle (data not shown). The 0.15 mM dose of 15d-PGJ2 (475 ng/paw) is similar to another study (300 ng/paw), which also did not report nocifensive behavior .
Behavioral desensitization of 15d-PGJ2 versus AITC
Previously it was reported that the second response to ipl. injection of 0.1% (10 mM) AITC, administered 15 min after the first injection, is significantly reduced in rats . However, another more recent study in mice demonstrated that nocifensive responses to the second injection of 10 mM AITC, administered 10 min after the first, sensitize significantly . The discrepancy between these two studies could arise from differences in dosing protocols or due to species differences. We determined whether 15d-PGJ2 inhibits TRPA1-dependent nociception in vivo via a simple cross-desensitization mechanism and whether this property of 15d-PGJ2 is distinct from AITC. Our experiment was designed to more carefully examine behavioral desensitization of 15d-PGJ2 vs. AITC responses in vivo. We used a 1 h inter-stimulus interval to correspond with our dosing paradigm(s) in the above CFA model. In addition, our design aimed to ensure that nocifensive responses to the first dose of both compounds had completely subsided prior to administering the second dose.
We first examined desensitization of behavioral responses to repeated 15d-PGJ2 stimuli and tested whether 15d-PGJ2 could inhibit subsequent responses to AITC. Unlike the AITC multi-dose results (Figure 3B), two injections (10 μL each, ipl.) of 15 mM 15d-PGJ2 produced significant reductions of the second nocifensive response to 15 mM 15d-PGJ2 and to AITC at 15 mM and at concentrations as high as 50 mM (Figure 3A and data not shown). The anti-nociceptive effect of 15 mM 15d-PGJ2 was locally mediated as ipl. injection in the contralateral hindpaw 1 h prior to ipl. injection of AITC did not significantly reduce AITC-induced nocifensive behavior (total nocifensive response 83 ± 15 sec vs. 97 ± 7 sec, p > 0.05).
Next, we tested whether 15 mM AITC could inhibit nocifensive responses to a subsequent injection of 15 mM 15d-PGJ2 via cross-desensitization. Pre-injection of 15 mM AITC did not induce cross-desensitization of behavioral responses to 15 mM 15d-PGJ2 (10 μL each, ipl.) (Figure 3B). We also did not observe homologous behavioral sensitization or desensitization as the nocifensive response to a second injection of 15 mM AITC was equivalent to that evoked by 15 mM AITC administered 1 h prior (and relative to vehicle pre-injection) (Figure 3B). The highest tested dose of AITC (50 mM) also did not inhibit nocifensive responses to a subsequent injection of 15 mM 15d-PGJ2 (1 h inter-stimulus; data not shown). These data demonstrate that behavioral desensitization to a second TRPA1-dependent noxious stimulus is not due to the noxious nature of the first stimulus. These data suggest that 15d-PGJ2 induces behavioral desensitization to itself and to AITC. In contrast, ATIC does not induce desensitization to itself or 15d-PGJ2.
15d-PGJ2 vs. AITC inhibition in DRG
In our previous publication characterizing 15d-PGJ2 activation of TRPA1-expressing DRG neurons, we showed that 15d-PGJ2 activated ~19% of total DRG neurons and that 98% of these also responded to AITC. We also demonstrated that 15d-PGJ2 responses by DRG neurons were absent in cultures derived from TRPA1−/− mice . Collectively, these data indicate that 15d-PGJ2 is a selective agonist at TRPA1. We further hypothesized that a potential mechanism for the reported anti-nociceptive properties of 15d-PGJ2 [9, 19, 20] is excitation and subsequent inhibition/desensitization of DRG neurons expressing TRPA1. Therefore, in order to evaluate whether 15d-PGJ2 could desensitize TRPA1-expressing nociceptors to other agonists, we utilized Fura-2 Ca2+ imaging in DRG neurons, to compare responses to 15d-PGJ2 and AITC in vehicle-, 15d-PGJ2- and AITC- pre-stimulated cultures.
We conducted cross- and homologous-inhibition experiments utilizing two bath applied pulses of 50–100 μM 15d-PGJ2 or AITC. As shown in Figure 4, 100 μM 15d-PGJ2 strongly inhibits subsequent responses to a pulse of 100 μM AITC applied up to 8 min later (Figure 4A) and to itself (Figure 4B). Similarly, 100 μM ATIC strongly desensitizes subsequent responses to 100 μM 15d-PGJ2 (Figure C) and to itself (Figure 4D). Cross-desensitization was maintained when we applied two pulses of 50 μM of each compound (data not shown). In experiments utilizing two 50 μM pulses of 15d-PGJ2 or two 50 μM pulses of AITC, homologous desensitization of 15d-PGJ2, but not AITC, was maintained (Figure 5). With up to an 8 min inter-stimulus interval, two 50 μM 15d-PGJ2 pulses revealed a significant homologous desensitization of the second 15d-PGJ2 response (Figure 5A). Intriguingly, the reverse was not evident—50 μM AITC did not inhibit the percentage of neurons responding (39.7% vs. 38.2%) or reduce the overall magnitude of responses to a subsequent stimulus of 50 μM ATIC (Figure 5B). Instead, the second response to 50 μM AITC was significantly sensitized relative to the first (Figure 5C). These experiments reveal complex concentration- and stimulus-dependent variables that affect TRPA1 activation.
15d-PGJ2 inhibits AITC, but not CAP responses
Previous behavioral studies in rats demonstrated heterologous desensitization between TRPA1 and TRPV1 in vivo [26, 28]. A pre-injection of 10 mM (0.1%) AITC administered 15 min prior to 10 μg CAP, significantly reduces CAP-induced nocifensive behavior compared to vehicle pre-treatment . To investigate whether 15d-PGJ2 could desensitize CAP responses in vivo, we utilized the same injection protocol as with our 15d-PGJ2 and AITC desensitization studies, injecting 15 mM 15d-PGJ2 1 h prior to 1.5 μg CAP. We did not observe 15d-PGJ2-induced behavioral heterologous desensitization of CAP in vivo (Figure 6A).
Next, we investigated whether 15d-PGJ2 can directly inhibit CAP-responsiveness of DRG neurons. TRPA1 is expressed in a subset of TRPV1-expressing neurons . Several studies have documented the phenomenon of heterologous desensitization between TRPA1 and TRPV1 using heterologous expression systems and cultured sensory neurons [26, 28–30]. To determine whether 15d-PGJ2 can inhibit subsequent responses to CAP, we pre-exposed DRG neurons to 100 μM 15d-PGJ2 vs. vehicle and compared the number and magnitude of CAP responders in the two groups. As illustrated in Figure 6B, 15d-PGJ2 did not inhibit CAP responses relative to 0.1% DMSO (vehicle). Neither the total number of neurons responding to CAP (66% vs. 58% of total neurons, p > 0.5) nor the magnitude of these responses (ΔF/F = 4.2 vs. 3.8, p > 0.5) was affected by pre-application of 15d-PGJ2 relative to vehicle. These findings correlate with our behavioral results and indicate that 15d-PGJ2 does not produce heterologous inhibition of TRPV1 via its activation of TRPA1.
Effects of 15d-PGJ2 are TRPA1-dependent
Previous studies have applied pharmacological inhibition and gene knockout approaches to characterize the role of TRPA1 in mechanohypersensitivity in vivo. Studies using TRPA1−/− mice suggest that TRPA1 is not involved in the induction of nerve injury- or inflammation-induced hypersensitivity, as TRPA1−/− mice develop hypersensitivity equivalent to WT. However, TRPA1 antagonists (AP-18 and HC-030031) ameliorate post-insult mechanical thresholds in WT but not TRPA1 −/− mice [21, 22].
To address the possibility that 15d-PGJ2 inhibits DRG neuron responses to AITC via a mechanism separate from TRPA1 activation, we performed co-application studies in DRG using HC-030031, a selective TRPA1 antagonist. After a 4 min exposure to 100 μM 15d-PGJ2 in the presence of antagonist, 50 μM AITC responses of DRG neurons were equivalent to those after vehicle exposure (Figure 7A and data not shown). These data support that the inhibitory effect of 15d-PGJ2 pre-application on DRG neuron responses to AITC is mediated via TRPA1. We also examined the reversibility of desensitization of TRPA1 in DRG neurons by 15d-PGJ2. As shown in Figure 7B, 100 μM 15d-PGJ2 inhibited subsequent responses to 50 μM AITC for up to 16 min (4–16 min intervals tested) with continuous washout, while 50 mM KCl responses were unaltered, indicating that general neuronal viability remained intact.
Next we determined whether the observed reduction in CFA-induced mechanical hypersensitivity was due to a TRPA1-specific effect of 15d-PGJ2 by repeating the CFA model in groups of TRPA1−/− and WT mice. Whereas 15d-PGJ2 caused a rebound of mechanical sensitivities toward baseline in WT mice, this effect was completely absent in TRPA1−/− mice (Figure 7C). These data suggest that the reduction of inflammatory hypersensitivity by 15d-PGJ2 is dependent on TRPA1 and taken together our data demonstrate a mechanism involving channel desensitization.
15d-PGJ2 tolerance and neurotoxicity
In order to evaluate the therapeutic utility of 15d-PGJ2 in long-term inflammatory hypersensitivity, we utilized a multi-dose protocol. We tested whether repeated doses of 15d-PGJ2, administered over the course of days, would continue to be effective in reducing CFA-induced inflammatory mechanical hypersensitivity. As shown in Figure 8, single daily doses of 15 mM 15d-PGJ2 (10 μL, ipl.) repeatedly attenuated mechanical hypersensitivity. To rule out that this effect was due to toxicity or damage of TRPA1-expressing peripheral fibers, we compared AITC responses 48 h after the last dose of 15d-PGJ2. We detected no difference in nocifensive behaviors of vehicle- vs. 15d-PGJ2-injected groups in response to an injection of 50 mM AITC (10 μL, ipl.) (Figure 8 inset; also note potentiation of AITC response in CFA model).
The primary hypothesis driving our investigation described here is that pre-treatment with 15d-PGJ2 protects against TRPA1-mediated nociception and hypersensitivity via inhibition of TRPA1 signaling in nociceptive neurons. Our behavioral data correspond to our observations in DRG sensory neurons. Our results obtained using the acute AITC model suggest that 15d-PGJ2 is sufficient to inhibit acute TRPA1-dependent nociception. Moreover, our findings support that a TRPA1-dependent mechanism contributes to the ability of 15d-PGJ2 to reduce established inflammatory mechanical hypersensitivity. Finally, we have probed the utility of 15d-PGJ2 (a TRPA1 agonist) as a potential therapeutic and find that analgesic effects are maintained over the course of days with repeated dosing.
All TRPA1 agonists identified to date induce nociceptive behavior in rodents or burning sensations in humans (for review) [31–33]. Similarly, we and others have shown that 15d-PGJ2 (10–47.4 μg/paw) causes robust nocifensive behavior in WT, but not TRPA1−/−, mice [6, 7]. These data suggest that 15d-PGJ2 (at these concentrations) induces nocifensive behavior that is specific to TRPA1 activation. In contrast, several studies have identified potent anti-nociceptive properties of 15d-PGJ2. These studies do not report nocifensive behavior in response to intrathecal (100 μg/site), intraganglionar (100 ng/site), ipl. (30–300 ng/paw) or temporomandibular joint (10–100 ng/site) injection of 15d-PGJ2. Concentrations of 15d-PGJ2 shown to inhibit nociception in these studies are typically lower than those we have tested here (474 ng-47.4 μg/paw) [6, 9, 19, 20].
In our view, it remains unclear whether the high concentrations of endogenous ligands we and others have tested for their nociceptive- and anti-nociceptive effects are physiologically relevant to pain modulation or to TRPA1 modulation in vivo. For example, inflammatory exudate concentrations of 15d-PGJ2 rise coincident to the resolution of the inflammatory state. Levels detected range between ~0.5 to 5 ng/ml—orders of magnitude lower than those we and others have potentially introduced by ipl. injection [34, 35]. There is currently no in vitro data on the time course or kinetics of occupancy of TRPA1 receptors by 15d-PGJ2. We are actively attempting to investigate this question and resolve the putative differences in agonist modulation at the channel level. We also currently have no method of ascertaining whether we are actively inhibiting TRPA1 channels at sub-cutaneous nociceptive fibers at the concentration(s) and dosing paradigm(s) we have utilized. However, 15d-PGJ2 is not broken down further enzymatically or non-enzymatically. Though it is a reactive electrophile, 15d-PGJ2 is highly stable in aqueous phase; when aqueous solutions are spiked with radioactively labeled 15d-PGJ2, the compound is 100% recoverable after 48 hours .
This prostaglandin metabolite also has anti-inflammatory and anti-nociceptive effects that are TRPA1-independent. For example, Napimoga et al. (2008) reported the anti-nociceptive property of 15d-PGJ2 is mediated in part by PPARγ and peripheral opioid receptors, as antagonists targeting both receptors inhibited effects of 15d-PGJ2 against PGE2-induced “hypernociception.” This study also examined the anti-nociceptive effect of 15d-PGJ2 in the formalin model of temporomandibular joint inflammation and ipl. delivery of carrageenan, finding that it attenuated mechanical “hypernociception” in both models. They hypothesize that increases in the macrophage population in the periphery contributed to the enhancement the anti-nociceptive effects of 15d-PGJ2 . Whereas we are examining its action in strictly the pain neuraxis involving primary TRPA1-expressing peripheral nociceptors, perhaps the effects of 15d-PGJ2 on macrophages and/or opioids are downstream of signaling through primary afferents expressing TRPA1. For instance, activation of TRPA1-expressing nociceptors could result in their release of factors that contribute to an immune response (i.e. 15d-PGJ2 release) or endogenous opioid signaling.
Differential behavioral and cellular effects of TRPA1 agonists
Previously published studies characterizing single-dose AITC-induced nocifensive responses in mice have utilized injections of 0.1-0.75% (10–75 mM, ipl.), while most behavioral desensitization studies using repeated AITC stimuli have utilized ≤ 20 mM. (e.g. [3, 26, 27]). Therefore, we compared behavioral desensitization to repeated AITC- and 15d-PGJ2-stimuli at two concentrations within this range. Using our dosing protocol, nocifensive responses to AITC did not desensitize. In contrast, 15d-PGJ2 evoked a significant desensitization to itself and AITC. Unlike previous studies using multi-dose protocols, we have administered agonists 1 h apart, which might account for the differences between our results and those of other studies, which report desensitization [26, 29, 37] or sensitization  by AITC. We hypothesize that the difference in the effects of 15d-PGJ2 and AITC on heterologous and homologous inhibition might result via differential acute and pharmacological desensitization of TRPA1 in vivo produced by the two agonists at various concentrations. Furthermore, topically applied and injected AITC causes an inflammatory response, including plasma extravasation and tissue edema, while there is no evidence supporting that 15d-PGJ2 promotes such responses [38, 39].
To our knowledge, this is the first study to closely examine bidirectional cross-inhibition of DRG neurons by exposure to two different TRPA1 agonists. The mechanisms underlying the different effects of AITC and 15d-PGJ2 remain unclear (see also below). Since Ca2+ imaging does not directly measure desensitization, electrophysiological and further cellular studies are warranted to directly measure the mechanisms of desensitization, as well as desensitization kinetics, stimulus- and concentration-dependence. Key to our conclusions regarding inhibition of TRPA1 signaling by 15d-PGJ2, we have attempted to make our stimulus and recording approach(es) as systematic as possible in order to reveal differential modulation of TRPA1 by 15d-PGJ2 vs. AITC. First, our review of the available literature indicated to us that ~100 μM concentrations of 15d-PGJ2 and AITC are saturating in calcium imaging analyses of cultured sensory neurons [7, 40]. We have confirmed these findings using our DRG culture and stimulus protocols. Similar to previously published EC50 data derived from heterologous expression studies of TRPA1 channels, we found 15d-PGJ2 and AITC to be of similar potency in their activation of TRPA1-expressing DRG neurons [6–8, 11, 40].
In DRG neurons, we observed strong homologous desensitization of AITC responses and cross-desensitization of 15d-PGJ2 in response to a pre-pulse of 100 μM AITC. Similarly, 100 μM 15d-PGJ2 inhibited subsequent responses to itself and to 100 μM AITC. Our results agree with those of Taylor-Clark et al. who reported that pre-treatment of trigeminal sensory neurons with 100 μM AITC significantly diminished subsequent responses to both 100 μM AITC and 15d-PGJ2 . While the majority of our studies examined the inhibitory efficacy of 100 μM 15d-PGJ2, we also investigated cross- and homologous desensitization using 50 μM concentrations of these compounds. We found that 50 μM AITC no longer exhibited these properties, whereas 15d-PGJ2 did at this lower concentration. Our data evince different magnitudes of homologous and heterologous inhibition evoked by these two compounds, each with steep time- and concentration-dependence, again the mechanisms of which remain uncertain.
A number of reports have demonstrated that similar to heat- and capsaicin-activated TRPV1, TRPA1 exhibits strong desensitization and tachyphylaxis , [29, 40] . However, a more recent study partially refutes these data, showing that TRPA1 also undergoes sensitization and trafficking to the plasma membrane in response to AITC and inflammatory mediators in vitro and in vivo . On balance, the results of our current study and those of previous studies reveal that sensitization/desensitization could be dependent on many variables, including agonist concentration, stimulus sequence, stimulus duration and inter-stimulus interval.
TRPV1 and TRPA1 are co-expressed in DRG neurons with TRPA1 labeling a subset of TRPV1 neurons . Studies of the two channels in CHO cell overexpression and DRG neurons show that when co-expressed, TRPA1 undergoes heterologous and homologous desensitization via CAP (TRPV1 agonist) and AITC stimuli, respectively. A proposed mechanism of TRPA1 desensitization in this manner is through TRPV1-directed internalization [26, 29]. It is intriguing that AITC is able to inhibit subsequent behavioral and neuronal responses to CAP, but 15d-PGJ2 (at the concentrations we have tested) is not, thus further highlighting the differential effects of these two TRPA1 agonists. Similar to Taylor-Clark et al. but in contrast to the findings of other groups, we find that pre-treatment with a TRPA1 agonist (in our case, 15d-PGJ2) in sensory neurons does not inhibit subsequent responses to CAP . Correspondingly, we also did not observe behavioral desensitization to CAP as a result of 15d-PGJ2 pre-treatment, indicating that the inhibition is TRPA1 specific.
Although both compounds are electrophiles that activate TRPA1 via covalent modification of key cysteine (or other) residues, it is quite plausible that AITC and 15d-PGJ2 activate the channel differently, perhaps via differential modulation of required cysteines. For instance, there is indirect evidence that the cysteine required for 15d-PGJ2 activation in human TRPA1 is different than that required for activation by other compounds . Perhaps also the two compounds induce differential trafficking to the plasma membrane [see  that is dependent on concentration. Finally, intracellular signaling cascades upon TRPA1 activation could be ligand-dependent, but this has never been shown. These possibilities raise an interesting avenue of research and could be addressed in mutagenesis studies combined with approaches such mass spectroscopy.
TRPA1 and mechanosensitivity
We hypothesize that sufficient doses of 15d-PGJ2 effectively inhibit TRPA1 by desensitizing the channel. By applying this concept in our behavioral approaches to understanding the modulation of TRPA1 by 15d-PGJ2 in the CFA model of inflammatory hypersensitivity, we have essentially obtained the same results using a channel agonist as those studies which have utilized channel antagonists [21–23, 42]. While 15d-PGJ2 had no effect on naïve mechanical thresholds nor perturbed the development of mechanical hypersensitivity, it inhibited established inflammatory mechanical hypersensitivity in WT, but not TRPA1−/− mice. Although it appears that TRPA1 expression in peripheral mechanonociceptors is not required for the development of mechanical hypersensitivity, it is possible that sustained mechanical hypersensitivity results in part through an autocrine or paracrine positive feedback mechanism involving TRPA1. As TRPA1 is activated by products of cellular stress, factors released by mechanical damage could feed back on the channel. However, this possible signaling pathway does not resolve the conundrum of why TRPA1−/− mice develop and maintain mechanical hypersensitivity, but TRPA1 antagonists can inhibit inflammatory and neuropathic hypersensitivity via “on-target” mechanisms.
Conclusions and future directions
A goal of our studies was to determine whether 15d-PGJ2, or any strongly desensitizing TRPA1 agonist, could be useful as a pain therapeutic. For example, for a similar channel TRPV1, capsaicin is the active ingredient in over-the-counter and prescription topical treatments and provides effective relief of joint pain based on its ability to desensitize TRPV1-expressing fibers. Thus, TRPA1 agonists could serve a similar therapeutic role. Here we describe experiments in which we administered 15d-PGJ2, beginning 1 day after the induction of inflammation. Our dosing strategy repeatedly produced a ~2 h block of mechanical hypersensitivity as shown using the von Frey test. Our studies show the effectiveness of administering such a dose after, but not before, the development of inflammation or neuropathic injury. This is in accordance with the nature of pain treatment, which is given after a patient reports discomfort from inflammation or injury. With the route and concentration we tested in our multi-dose experiment (15 mM, ipl.), 15d-PGJ2 initially causes nocifensive responses, but appears to have no pro-inflammatory or neurotoxic effects on TRPA1-expressing neurons. Future studies will further test the efficacy of 15d-PGJ2 as a therapeutic by determining a dose or route of administration (e.g. oral or topical application) that causes minimal pain, while providing analgesic benefits.
Experiments were performed in accordance with the policies and recommendations of the National Institutes of Health and the International Association for the Study of Pain. Protocols were approved by the Animal Care and Use Committee of Washington University School of Medicine (St. Louis, MO). Mice were housed at ambient (22-25°C) temperature with a 12 h light–dark cycle. Cellular and behavioral assays were performed using 8- to 12-wk-old male C57BL/6 J and TRPA1 knockout mice. The TRPA1−/− strain was originally obtained from Kelvin Y. Kwan and David P. Corey . Heterozygous F2 crosses were set and behavioral tests carried out on male WT and TRPA1−/− littermates of 8–12 weeks of age.
Animals were placed in individual Plexiglas boxes (15X11X11 cm) either on a flat surface covered with an absorbent liner (chemical agonist tests) or on a wire mesh platform (von Frey tests) and acclimated for 1–2 h to the testing environment—an individually lighted, temperature-controlled room (22-25°C) equipped with a white noise generator. Experimenters were blind with respect to treatment and genotype. Sample sizes are indicated in Figure legends.
For dose–response experiments, mice were injected on the plantar surface of the right hindpaw with 10 μL of 0.15 (.474 μg), 1.5 (4.74 μg) or 15 mM (47.4 μg) 15d-PGJ2 diluted in 5% EtOH, 0.9% NaCl (vehicle). Nocifensive behavior (licking and deliberate lifting and shaking of the injected hindpaw) was recorded at 5- to 10-min intervals for 1 h. For multi-dose 15d-PGJ2 experiments, mice received two ipl. injections of 10 μL 1.5 or 15 mM 15d-PGJ2 1 h apart. For multi-dose AITC experiments, mice received two ipl. injections of 10 μL of either 0.15 mM (0.0015%), 1.5 mM (0.015%) or 15 mM, (0.15%) AITC (diluted in mineral oil) 1 h apart. Nocifensive behavior was recorded at 5- to 10-min intervals for 1 h.
To test for 15d-PGJ2-induced inhibition of nociceptive responses to AITC or CAP, groups of mice were first injected on the plantar surface of the right hindpaw with 10 μL of 1.5 or 15 mM 15d-PGJ2 or vehicle. 1 h later, an injection of 10 μL AITC or 10 μL CAP (1.5 μg) was administered to the same paw. For these tests, nocifensive behaviors (licking and deliberate lifting and shaking of the injected hindpaw) in response to the second injection were recorded at 5- to 10-min intervals until they completely subsided—1 h for AITC and 15 min for CAP. We also tested whether ipl. injection of 10 μL 15 mM AITC was able to inhibit subsequent responses to an injection of 15 mM 15d-PGJ2 administered to the same paw 1 h later.
To determine whether inhibition of AITC responses by 15d-PGJ2 were locally mediated, we also performed a set of experiments in which we injected the left hindpaw of two groups of mice with 15 mM 15d-PGJ2 or vehicle and the right hindpaw with 15 mM AITC 1 h later. Nocifensive behaviors in response to the second AITC injection in the right hindpaw were compared between the two groups injected with 15d-PGJ2 or vehicle in the left hindpaw.
Mechanical hypersensitivity tests
We measured mechanical sensitivities with calibrated von Frey hairs using the up-and-down method modified for mice . We first investigated whether an ipl. injection of 10 μL 1.5 or 15 mM 15d-PGJ2 vs. vehicle had any effect on basal mechanical sensitivity. These experiments were performed by acquiring baseline von Frey measurements and then injecting 15d-PGJ2 or vehicle (5% EtOH, 0.9% NaCl) into the right hindpaw. Subsequent von Frey measurements of the ipsi- and contralateral hindpaws were taken at 1, 2, 6, 24 and 48 h post-injection.
In a separate set of experiments, we evaluated the effects of 15d-PGJ2 on CFA-induced inflammatory mechanical hypersensitivity. On day 0, baseline sensitivity to von Frey stimulation was measured prior to ipl. injection of 10 μL CFA to the right hindpaw of mice. 24 h after CFA injection (day 1), von Frey sensitivities were measured again to determine the level of mechanical hypersensitivity in the CFA vs. vehicle groups. At the conclusion of these von Frey measurements, CFA-injected mice were randomly assigned to two groups and received either an ipl. injection of 10 μL 15 mM 15d-PGJ2 or vehicle to the right hindpaw. One h after this second injection, von Frey measurements were taken again at 1, 2, 4, 6 and 24 h post-injection. To examine the effect of repeated dosing of 15d-PGJ2, we performed this procedure as above through day 1 and then repeated it on days 2–4. Therefore, in this set of experiments, we made von Frey measurements on days 0–4 at the following time points: baseline (day 0), 24 h post-CFA (or vehicle) injection (day 1) and then 1, 2 and 24 h post-15d-PGJ2 (or vehicle) injection (days 1–4). To test for maintenance of nociceptive responses to TRPA1 activation, all mice were administered an ipl. injection of 10 μL 50 mM AITC at the conclusion of our repeated 15d-PGJ2 dosing experiment.
In another set of experiments on groups of WT and TRPA1−/− mice, we repeated this procedure as in day 1 above, but only up to 2 h post-15d-PGJ2 or vehicle injection (observed time of maximal 15d-PGJ2 effect on CFA-induced mechanical hypersensitivity).
Heat hypersensitivity test
Thermal sensitivity was measured using the Hargreaves test . Mice were placed in Plexiglas chambers on a heated (30°C) glass surface and acclimated to the apparatus and testing environment for 1 h. Radiant heat of constant intensity was applied to the plantar surface of the ipsilateral hindpaw using a 390 G Plantar Test Apparatus (IITC Life Sciences, Woodland Hills, CA). Withdrawal latency was calculated as the time from stimulus initiation until paw withdrawal with a 20 s cutoff to prevent tissue damage. The test was repeated 3 times (~15 min between tests of same paw) and the withdrawal latencies of the 3 repetitions averaged.
DRG culture and calcium imaging
Dissociated DRG cultures derived from male C57BL/6 J mice were prepared and plated onto polyornithine- and laminin-coated coverslips as described [45, 46]. For each experimental condition we performed imaging on at least 2 separate cultures derived 4 animals. These cultures yielded ~ 8 coverslips each on which we performed paired comparisons (e.g. 100 μM AITC vs. 100 μM 15d-PGJ2). Agonist-induced responses of DRG neurons were analyzed using Fura-2 (Invitrogen) ratiometric calcium imaging 24 h after plating. Wash, vehicle and compound solutions contained HEPES buffered saline with 2 mM calcium. We exposed cells to 50 mM potassium at the end of experiments as a control for viable neurons. We defined neuronal responses as ≥ 20% increase of the Fura-2 ratio from baseline, with the exception of some dose-inhibition experiments (see Results). For all experiments, the compound exposure and wash-out durations are noted in each Figure and/or corresponding legend.
The concentrations of compounds used in cross-desensitization studies were as follows: 50 μM and 100 μM 15d-PGJ2, 50 μM and 100 μM AITC and 1 μM CAP. We compared the responses of neurons to AITC and CAP from the 15d-PGJ2-treated groups to those of the vehicle-treated (0.1% DMSO) groups. To investigate the duration of desensitization of the AITC response induced by pre-exposure to 15d-PGJ2, we exposed the cells to either 50 μM AITC or 100 μM 15d-PGJ2 for 1 min, washed continuously with buffer solution for up to 16 min and then re-exposed the cells to 50 μM AITC.
Finally, to test whether inhibition of AITC responses by 15d-PGJ2 was mediated specifically by TRPA1, we utilized the TRPA1-specific antagonist HC-030031. We compared the magnitude and frequency of AITC responses after 15d-PGJ2 exposure vs. 15d-PGJ2 exposure in the presence of the antagonist.
Student’s t-tests or Mann Whitney U-tests were used to analyze data where appropriate; the tests used are indicated in the Figure legends. Repeated measures analysis of variance (RMANOVA) with Bonferroni post-hoc correction was used to test changes in nociceptive behaviors over time in the AITC and CAP inhibition tests and in the CFA model of inflammatory hypersensitivity. All behavioral data were analyzed using Prism 5.0. Data from DRG studies were analyzed using OriginPro 8.1 (OriginLab Corp., Northampton, MA 01060) and Prism 5.0 (GraphPad Software Inc., San Diego, CA). In all studies, statistical significance is set at p < 0.05 and data are presented as mean ± S.E.M.
AITC, CAP and CFA were purchased from Sigma Chemical Company. 15d-PGJ2 was purchased from Enzo Life Sciences. HC-030031 was purchased from Santa Cruz. For behavioral experiments, stock solutions of 15d-PGJ2 or CAP were dissolved in ethanol and diluted in normal saline solution (0.9% NaCl) so that the final concentration of EtOH was ≤ 5%. Solutions of AITC were prepared by suspending directly in mineral oil. For calcium imaging experiments, stock solutions of 15d-PGJ2, AITC and CAP were dissolved in DMSO or ethanol and used at a final solvent concentration of ≤ 0.1% in buffer solution.
Transient receptor potential cation channel subfamily A member 1
- 15d-PGJ2 :
15-Deoxy-Δ12, 14-prostaglandin J2
- TRPA1−/− :
TRPA1 knockout (null).
Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, et al.: ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003,112(6):819–829. 10.1016/S0092-8674(03)00158-2
Patapoutian A, Peier AM, Story GM, Viswanath V: ThermoTRP channels and beyond: mechanisms of temperature sensation. Nature reviews 2003,4(7):529–539. 10.1038/nrn1141
Kwan KY, Allchorne AJ, Vollrath MA, Christensen AP, Zhang DS, Woolf CJ, Corey DP: TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 2006,50(2):277–289. 10.1016/j.neuron.2006.03.042
Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, Basbaum AI, Julius D: TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006,124(6):1269–1282. 10.1016/j.cell.2006.02.023
Karashima Y, Talavera K, Everaerts W, Janssens A, Kwan KY, Vennekens R, Nilius B, Voets T: TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci USA 2009,106(4):1273–1278. 10.1073/pnas.0808487106
Cruz-Orengo L, Dhaka A, Heuermann RJ, Young TJ, Montana MC, Cavanaugh EJ, Kim D, Story GM: Cutaneous nociception evoked by 15-delta PGJ2 via activation of ion channel TRPA1. Mol Pain 2008, 4: 30. 10.1186/1744-8069-4-30
Andersson DA, Gentry C, Moss S, Bevan S: Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 2008,28(10):2485–2494. 10.1523/JNEUROSCI.5369-07.2008
Taylor-Clark TE, Undem BJ, Macglashan DW Jr, Ghatta S, Carr MJ, McAlexander MA: Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1). Mol Pharmacol 2008,73(2):274–281.
Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK: Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008,9(7):639–649. 10.1016/j.jpain.2008.02.002
Scher JU, Pillinger MH: The anti-inflammatory effects of prostaglandins. J Investig Med 2009,57(6):703–708.
Takahashi N, Mizuno Y, Kozai D, Yamamoto S, Kiyonaka S, Shibata T, Uchida K, Mori Y: Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators. Channels (Austin) 2008,2(4):287–298. 10.4161/chan.2.4.6745
Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000,403(6765):103–108. 10.1038/47520
Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK: 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000,97(9):4844–4849. 10.1073/pnas.97.9.4844
Cernuda-Morollon E, Pineda-Molina E, Canada FJ, Perez-Sala D: 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001,276(38):35530–35536. 10.1074/jbc.M104518200
Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H: Alpha, beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. J Biol Chem 2005,280(14):14145–14153. 10.1074/jbc.M500901200
Shiraki T, Kodama TS, Shiki S, Nakagawa T, Jingami H: Spectroscopic analyses of the binding kinetics of 15d-PGJ2 to the PPARgamma ligand-binding domain by multi-wavelength global fitting. Biochem J 2006,393(Pt 3):749–755.
Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A: Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 2007,445(7127):541–545. 10.1038/nature05544
Hinman A, Chuang HH, Bautista DM, Julius D: TRP channel activation by reversible covalent modification. Proc Natl Acad Sci USA 2006,103(51):19564–19568. 10.1073/pnas.0609598103
Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga JT, Parada CA, Verri WA Jr, Cunha FQ, Ferreira SH: 15d-prostaglandin J2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor. J Pharmacol Exp Ther 2008,324(1):313–321.
Pena-dos-Santos DR, Severino FP, Pereira SA, Rodrigues DB, Cunha FQ, Vieira SM, Napimoga MH, Clemente-Napimoga JT: Activation of peripheral kappa/delta opioid receptors mediates 15-deoxy-(Delta12,14)-prostaglandin J2 induced-antinociception in rat temporomandibular joint. Neuroscience 2009,163(4):1211–1219. 10.1016/j.neuroscience.2009.07.052
Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, Patapoutian A: A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 2007, 3: 40. 10.1186/1744-8069-3-40
Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, Henze DA, Kane SA, Urban MO: HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain 2008, 4: 48. 10.1186/1744-8069-4-48
da Costa DS, Meotti FC, Andrade EL, Leal PC, Motta EM, Calixto JB: The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation. Pain 2010,148(3):431–437. 10.1016/j.pain.2009.12.002
Tsagareli MG, Tsiklauri N, Zanotto KL, Carstens MI, Klein AH, Sawyer CM, Gurtskaia G, Abzianidze E, Carstens E: Behavioral evidence of thermal hyperalgesia and mechanical allodynia induced by intradermal cinnamaldehyde in rats. Neurosci Lett 2010,473(3):233–236. 10.1016/j.neulet.2010.02.056
Wei H, Chapman H, Saarnilehto M, Kuokkanen K, Koivisto A, Pertovaara A: Roles of cutaneous versus spinal TRPA1 channels in mechanical hypersensitivity in the diabetic or mustard oil-treated non-diabetic rat. Neuropharmacology 2010,58(3):578–584. 10.1016/j.neuropharm.2009.12.001
Ruparel NB, Patwardhan AM, Akopian AN, Hargreaves KM: Homologous and heterologous desensitization of capsaicin and mustard oil responses utilize different cellular pathways in nociceptors. Pain 2008,135(3):271–279. 10.1016/j.pain.2007.06.005
Schmidt M, Dubin AE, Petrus MJ, Earley TJ, Patapoutian A: Nociceptive signals induce trafficking of TRPA1 to the plasma membrane. Neuron 2009,64(4):498–509. 10.1016/j.neuron.2009.09.030
Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM: Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 2008,28(5):1064–1075. 10.1523/JNEUROSCI.1565-06.2008
Akopian AN, Ruparel NB, Jeske NA, Hargreaves KM: Transient receptor potential TRPA1 channel desensitization in sensory neurons is agonist dependent and regulated by TRPV1-directed internalization. J Physiol 2007,583(Pt 1):175–193.
Salas MM, Hargreaves KM, Akopian AN: TRPA1-mediated responses in trigeminal sensory neurons: interaction between TRPA1 and TRPV1. Eur J Neurosci 2009,29(8):1568–1578. 10.1111/j.1460-9568.2009.06702.x
Tai C, Zhu S, Zhou N: TRPA1: the central molecule for chemical sensing in pain pathway? J Neurosci 2008,28(5):1019–1021. 10.1523/JNEUROSCI.5237-07.2008
Patapoutian A, Tate S, Woolf CJ: Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 2009,8(1):55–68. 10.1038/nrd2757
Basbaum AI, Bautista DM, Scherrer G, Julius D: Cellular and molecular mechanisms of pain. Cell 2009,139(2):267–284. 10.1016/j.cell.2009.09.028
Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM, Gilroy DW: Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA 2007,104(52):20979–20984. 10.1073/pnas.0707394104
Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999,5(6):698–701. 10.1038/9550
Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA: Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 2003,112(6):945–955.
Ruparel NB, Patwardhan AM, Akopian AN, Hargreaves KM: Desensitization of TRPA1 by the TRPV1-selective cannabinoid arachidonoly-2 chloroethanolamine (ACEA). Mol Pharmacol 2011,80(1):117–123. 10.1124/mol.110.068940
Inoue H, Asaka T, Nagata N, Koshihara Y: Mechanism of mustard oil-induced skin inflammation in mice. Eur J Pharmacol 1997,333(2–3):231–240.
Grant AD, Pinter E, Salmon AM, Brain SD: An examination of neurogenic mechanisms involved in mustard oil-induced inflammation in the mouse. Eur J Pharmacol 2005,507(1–3):273–280.
Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, Julius D: Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004,427(6971):260–265. 10.1038/nature02282
Penuelas A, Tashima K, Tsuchiya S, Matsumoto K, Nakamura T, Horie S, Yano S: Contractile effect of TRPA1 receptor agonists in the isolated mouse intestine. Eur J Pharmacol 2007,576(1–3):143–150.
Wei H, Hamalainen MM, Saarnilehto M, Koivisto A, Pertovaara A: Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology 2009,111(1):147–154. 10.1097/ALN.0b013e3181a1642b
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994,53(1):55–63. 10.1016/0165-0270(94)90144-9
Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988,32(1):77–88. 10.1016/0304-3959(88)90026-7
Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A: Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004,41(6):849–857. 10.1016/S0896-6273(04)00150-3
Vilceanu D, Honore P, Hogan QH, Stucky CL: Spinal nerve ligation in mouse upregulates TRPV1 heat function in injured IB4-positive nociceptors. J Pain 2010,11(6):588–599. 10.1016/j.jpain.2009.09.018
We thank Michael R. Bruchas, Joe Henry Steinbach, Edward Siuda, Robert Gereau, Ardem Patapoutian and Manuela Schmidt for invaluable input in the preparation of this manuscript. We also thank David Corey and Kelvin Kwan for the generous contribution of the founder strain of TRPA1 knockout mice. This work was funded by the National Institutes of Health, Institute of Neurological Disorders and Stroke, grant NS067338 to G.M.S. and NS40538 to C.L.S. and a Pilot and Feasibility grant from the Center for the Investigation of Membrane Excitability Diseases at Washington University to G.M.S. Additional support was from the China Scholarship Council to Y.W. and CAPES to P.A.B.
The authors have no financial or non-financial competing interests.
YW performed behavior experiments and statistical analyses of these. PAB assisted with the design and execution of behavioral studies with YW as well as performed Ca2+ imaging studies. MEB performed and analyzed AITC and 15d-PGJ2 desensitization studies in calcium imaging experiments. TBD and MJS performed and analyzed Ca2+ imaging studies of AITC and 15d-PGJ2 dose–response, cross-desensitization and antagonist studies. EQH, AMF, MW, VMW prepared all DRG cultures utilized by the GMS lab, performed all mouse husbandry and PCR genotyping of TRPA1−/− line and assisted with behavioral experiments. EAK performed and analyzed 15d-PGJ2-induced desensitization of CAP calcium imaging studies. CLS provided technical supervision of Ca2+ imaging studies, assisted in the design and analysis of these and helped to draft the manuscript. GMS conceived of the study, performed and supervised Ca2+ imaging and behavioral experiments, produced Figures and wrote the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Weng, Y., Batista-Schepman, P.A., Barabas, M.E. et al. Prostaglandin metabolite induces inhibition of TRPA1 and channel-dependent nociception. Mol Pain 8, 75 (2012). https://doi.org/10.1186/1744-8069-8-75